CSL HY profit at $US1b-plus for first time

February 14, 2018

Paul Perreault, CEO of CSL which has lifted its full-year profit by 35% to $US1.09 billion

Vaccines and blood products supplier CSL's half-year net profit has risen 34.9 per cent to $US1.09 billion ($A1.53 billion), boosted by robust demand for its products.

Sales revenue for the six months to December has come in 12.8 per cent higher at $US4.1 billion, and the company has declared an unfranked interim dividend of US79 cents a share, up 15 cents on last year.

The company now expects full-year net profit in constant currency terms to be in the range of $US1.55 billion to $US1.60 billion, after taking into account the seasonality of the influenza business and the timing of expenses.

More in National
Login Sign Up

Dummy text